The observed PKP2 dose-function relationship indicates that cardiac-selective AAV9:PKP2 gene therapy may be a promising therapeutic approach to treat ARVC patients with PKP2 mutations. This evidence concerns the gene PKP2 and Arrhythmogenic right ventricular dysplasia.